Lectures That Last
Dr. Willian da Silveira
Dr. da Silveira is currently a Lecturer in Molecular Genetics and Genomics at the Staffordshire University and an adjunct lecturer at the International Space University. He is also co-head of the Space Omics Topical Team funded by ESA.
Dr. da Silveira has a Bachelor’s degree in Pharmacy-Biochemistry, a Master’s degree in Biosciences applied to Pharmacy, and a Ph.D. in Medical Sciences, obtained at the University of São Paulo, Brazil. After the completion of his PhD, he became a Research Fellow in Bioinformatics Analysis at the Centre for Genomic Medicine (CGM) at the Medical University of South Carolina (MUSC). There, he focused on Big Data analysis and Omics advances and started his collaboration with NASA Genelab. In 2019 he assumed the role of Research Fellow in Food System Biology at the Queen´s University Belfast (QUB) investigating the effect of food contaminants in gene expression networks and senescence in primary prostate cells. In 2022 he was part of the Class-2 of the NASA STAR training program.
Dr. Sudipta “Nila” Devanath
Doctor. Lawyer. Dreamer. Leader.
Dr. Sudipta "Nila" Devanath is a doctor and lawyer working on acute care telemedicine in the U.S.
Dr. Devanath's journey began in Pittsburgh, PA, where she earned her bachelor of philosophy in neuroscience and psychology and bachelor of arts in sociology from the University of Pittsburgh. She started her M.D. at the University of Pittsburgh School of Medicine, but realized the interplay between medicine and law in the current policy landscape and wanted to combine these passions. In the middle of medical school, she took a leave of absence to earn her J.D. from Harvard Law School where Dr. Devanath also played a role in several leadership positions throughout the university including president of the graduate and professional student government. From there, she returned to Pittsburgh to complete her M.D., and after receiving her doctorates, she completed her medical training at Yale University in internal medicine, where she also held several leadership positions including co-president of all resident and fellow trainee employees at Yale.
She currently serves as the Associate Medical Director for Transitions of Care at Sentara Healthcare, a health system which includes 12 hospitals throughout the states of Virginia and North Carolina in the US. Before the COVID-19 pandemic, acute care telemedicine was close to science fiction, but with hospitals overburdened, new solutions to care for the sickest patients from the home needed to become a reality and fast. In Dr. Devanath's position, she was able to expand these programs throughout several hospitals helping to offload overwhelmed healthcare systems and innovate in systemic patient care while controlling the spread of disease. In her spare time she has spoken on the interplay between healthcare and politics, most recently speaking at the U.S. Capitol with Congresswoman Jayapal and House Speaker Nancy Pelosi on H.R. 3771, a bill in the U.S. House of Representatives aimed at increasing research efforts to study populations that are disproportionately affected by heart disease.
Lecture Title: Heart Disease and Treatment in Communities of Color
To listen the lecture, please Watch Here
Course-director of Artificial Intelligence
Based in London, Ajit’s work spans research, entrepreneurship, and academia relating to artificial intelligence (AI) with Cyber-Physical systems. He is the course director of the course: Artificial Intelligence: Cloud and Edge Implementations at the University of Oxford. He is also a visiting fellow in Engineering Sciences at the University of Oxford.
Besides this, he also conducts the University of Oxford courses: Digital Twins, Cybseecurity, and Agtech. Ajit works as a Data Scientist through his company, feynlabs – focusing on building innovative early-stage AI prototypes for complex AI applications.
Besides the University of Oxford, Ajit has also conducted AI courses at the London School of Economics (LSE), Universidad Politécnica de Madrid (UPM), and as part of The Future Society at the Harvard Kennedy School of Government. He is also working on a book to teach AI using mathematical foundations at the high school level.
Ajit is the Chief AI Officer of Digitty.io, a venture-funded company based in Berlin. His work at Oxford and his company is based on the interdisciplinary aspects of Artificial Intelligence, including AI with Digital Twins, AI with Quantum, AI for Metaverse, and AI in Agtech and Life Sciences.
His teaching is based on a methodology for AI and Cyber-Physical systems, which he is
developing as part of his teaching and research, especially for Engineering Sciences. His Ph.D. research is based on AI and Affective Computing (how AI interprets emotion). Ajit has contributed to the World Economic Forum and the European Parliament on
technology and AI themes. Ajit is interested in social causes and mentors young people at Oxford and beyond, especially for the Autism Spectrum and neurodiverse skill sets for learning Artificial Intelligence based on mathematical foundations.
Session 1: Introduction to Artificial Intelligence
To listen the lecture, please Watch Here
Session 2: Artificial Intelligence Exercise
To listen the lecture, please Watch Here
Founder and CEO
Dr. Mensah holds a BSc (Hons) in Biomedical Sciences degree from the University of the West of England, UK, a master’s degree in Medical Genetics & Immunogenetics from Brunel University, UK and a Triple Doctorate degree in Anatomy, Physiology and Genetics from University of Oxford, UK.He is the founder and executive director of The Pathway Initiative Inc (TPI) and the Gateway Institute of Medicine and Health Sciences (GIMHS). He sees the founding of The Pathway Initiative as a clarion call, as he has experienced first-hand the devastating impact of health inequality in underserved communities by the sudden loss of both parents six-months apart.
Dr. Mensah has over 15 yr. of experience in medical education, admissions, teaching, research, and student supervision. He trained as a scientist and researcher at the University of Cambridge, UK, Harvard Medical School, and Massachusetts Institute of Technology (MIT). His research publications span hemato-oncology, genetics, bioengineering, photomedicine and nanomedicine. He is a recipient of the prestigious International Young Investigator Scientific Award in hematology.
He has mentored over 35 students; some are now practicing physicians.
Given his own humble beginnings from a small town in Ghana, he strongly believes that no child’s future should be shackled by their socio-economic background.
Besides academia, he takes to his other passion which spans over two decades of church leadership and educational support to the youth in his local community. He credits his career journey to the amazing grace of the Lord. He is married to his beautiful wife, Rosemary, they are blessed with two children, Edna and Lawrence Jr.
Dr. Argita earned her PhD at the University of Birmingham, UK. Her research investigated the effects of two agonists on immune function with the goal of better understanding how stress affects the ability of the cytotoxic cells of the immune system to fight infection. Following her PhD, Dr. Argita carried out her postdoctoral research training at University College London, where she published several high-impact scientific journals in the field of psychology whilst collaborating with world-leading scientists, including a Nobel Prize winner.
While conducting scientific research, Argita also worked as a lecturer as she designed, taught, and directed several biomedical sciences courses for medical students. Argita was awarded the UCL medical students’ top teaching award for the neuro-immunology course she designed, delivered, and directed. After completing her first post-doc training, Dr. Argita moved to Imperial College London, where she conducted medical research in the field of haematology.
Her passion for higher education teaching led Dr. A Zalli to complete her MSc studies in University Learning and Teaching at Imperial College London, whilst working full time and being a mum. Over the past couple of years, Dr. Argita has focused on teaching and pedagogical training of university teaching staff, and she is currently a teaching and learning specialist lead in the Faculty of Medicine, clinical years.
Dr. Argita is also the co-founder of We Speak Science, a non-profit institution, the aim of which is to increase awareness of science and medicine in the USA and Europe. Through We Speak Science, Dr. Argita co-founded a charity called “Aferdita Ime,” in collaboration with other world-class oncologists and scientists, whose aim is to help cancer patients through psycho-social support and counselling.
Dr Argita co-founded a charity called “Aferdita Ime”, in collaboration with other world-class oncologists and scientists, whose aim is to help cancer patients through psycho-social support and counselling.
To relieve human suffering by the discovery and development of novel medicines to treat diseasesn of significant unmet need.
Robert A. Copeland, Ph.D. founded Accent Therapeutics, Inc. in September 2017 and serves as its President and Chief Scientific Officer. He is also President of the independent consulting firm, Ki Consultant, LLC. He was formerly President of Research and Chief Scientific Officer of Epizyme, Inc. and before that, Vice President of Cancer Biology, Oncology Center of Excellence in Drug Discovery, GlaxoSmithKline. Dr. Copeland serves on a number of advisory boards within industry, academia, professional societies and professional journals. He received his B.S. in chemistry from Seton Hall University, his doctorate in chemistry from Princeton University and did postdoctoral studies as the Chaim Weizmann Fellow at the California Institute of Technology. His research interest is in elucidating the determinants of drug recognition by their biological targets and the use of this information in the discovery and design of new medicines. He has contributed to drug discovery and development efforts leading to 19 investigational new drugs entering human clinical trials. These include the cancer drugs Tazverik™ (tazemetostat), Tafinlar™ (dabrafenib) and Mekinist™ (trametinib), the anemia drug Duvroq™ (daprodustat) and the antibiotic Altabax™ (retapamulin). Dr. Copeland has contributed more than 200 publications to the scientific literature, holds 14 issued U.S. patents and has authored 5 books in the areas of protein science and enzymology. In 2016 he was elected a Fellow of the American Association for the Advancement of Science (AAAS) and in 2020 he was elected a Fellow of the Royal Society of Chemistry.
David was born in Thurso, in Caithness and brought up in Bettyhill and Helmsdale in Sutherland. He learnt to fly in 1977 while studying Aeronautical Engineering at the University of Glasgow. After graduating he joined the Royal Air Force and flew the Harrier GR3 in what was then West Germany before being selected as an exchange student with the French Test Pilot School.
In 1988 he was posted to the Fixed Wing Test Squadron at Boscombe Down where, amongst other things, he carried out the first Harrier field site covert night operations, the first single seat low level night attack flights on the Harrier GR7, first ship compatibility trials on the Sea Harrier FA2, and first spinning trials on the Tucano basic trainer. He became Officer Commanding Fast Jet Test Flight in 1992 and in the same year was awarded the Air Force Cross by Her Majesty Queen Elizabeth II for his work there.
In 1993 he took up a position as an instructor at the Empire Test Pilots’ School at Boscombe Down and became Principal Fixed Wing Tutor in 1994. In 1995 he retired from the RAF and joined Virgin Atlantic, becoming a captain on the Boeing 747 and, later, on the Airbus 340.
Having evaluated the SpaceshipOne flight simulator in early 2004, David became involved in the Virgin Galactic project soon after its inception as its test pilot. In 2009 he joined the team full time and became Chief Pilot in 2011. He has over fifty flights in WhiteKnightTwo and seven powered flights in SpaceShipTwo, including three spaceflights.
David was also an historic aircraft display pilot in the UK for 22 years and has over 14,000 hours of flight time on around 150 different types from all eras in aviation, including the world’s oldest original flying aircraft, a 1909 Bleriot.
Vladimir Pletser earned a Master of Engineering in Mechanics in 1979, a Master of Sciences in Geophysics in 1980 and a Ph.D. in Astrophysics in 1990 from the University of Louvain, Belgium.
He is currently Director of Space Training Operations at Blue Abyss, a company based in UK, proposing a new approach for astronaut training.
From 2016 to 2018, he was Visiting Professor – Scientific Adviser at the Technology and Engineering Centre for Space Utilization of the Chinese Academy of Sciences in Beijing, China, supporting the preparation and development of microgravity research instrumentation for parabolic flights and for the future Chinese Space Station.
Previously, he worked for 30 years as Senior Physicist – Engineer at the European Space Research and Technology Centre (ESTEC) of the European Space Agency (ESA), developing scientific instruments for microgravity research in fluid physics, crystallisation of proteins and zeolites and on dexterous manipulation on board the International Space Station.
He was also responsible of the ESA aircraft parabolic flight programme. He logged more than 7350 parabolas, representing more than 39h 30m of weightlessness, equivalent to 26 Earth orbits, and 53 min and 50 min at Mars and Moon g levels, during which he participated in several hundred experiments in physical and life sciences.
He holds the official Guinness World Record for the number of airplanes (14) on which he flew parabolas. He served as Flight instructor for public Discovery Parabolic Flights. Astronaut Candidate for Belgium since 1991, he was Payload Specialist candidate for several Spacelab missions, including Spacelab LMS for which he spent two months in training at NASA-JSC, Houston, in 1995. He was Astronaut Training Instructor for Parabolic Flights with ESA astronauts and for NASA and DLR astronauts for several Spacelab missions.
Selected in 2001 by The Mars Society, a private organisation promoting the human exploration of Mars, he participated in three international simulation campaigns of Mars missions in the Arctic Circle in 2001 and in the Desert of Utah in 2002 and as Crew Commander in 2009.
He is visiting Professor in 20 universities in Europe, USA, Canada, Africa, Israel, and China. He has more than 650 publications, including 6 books, 16 book chapters, 63 articles in refereed journals and 138 articles in international conferences proceedings. He is member of the International Astronautical
Academy and of several other academies and scientific organizations.
Dr Zeka received her PhD in “Chemical Processes and Biotechnology Innovation” from L’Aquila University, in Italy, having investigated bioactive compounds in Crocus sativus. During the course of her PhD research, she actively sought and set up international collaborations, with placements in Japan and at De Montfort University, Leicester, UK, which resulted in original and review publications.
At the end of her PhD, Keti followed her developing interest in regenerative medicine and cancer and had the initiative to join the world-renowned Gurdon laboratory on an Erasmus+ fellowship for 6 months, where she had the chance to be acquire knowledge and expertise in epigenetics of nuclear reprogramming.
While studying chromatin modifiers, Dr Zeka became increasingly interested in these molecules’ capacity to catalyse post-translational modifications in non-histone proteins and how this activity may extend and complement their range of targets and effects at the level of chromatin.
Keti’s research at the University of Cambridge (UK) focused on the cross-talk
between epigenetics and metabolism in Acute Myeloid Leukemia (AML). Her studies have been supported by prestigious personal fellowships such as the Italian Association for Cancer Research (AIRC, 2016-2017), the Marie Curie Individual Fellowship (2018-2020) and the Cambridge Philosophical Society Postdoctoral Fellowship (2020). Since December 2020, Keti’s scientific curiosity has driven her postdoctoral journey to the Giustacchini Lab, at the UCL Zayed Centre for Research, to work on paediatric leukemic stem cells.
The importance of Keti’s project has been recognised through the prestigious award “Olivia Hodson Cancer Fund 2021”, a special purpose Fund within Great Ormond Street Hospital Children’s Charity and the UCL institute of Child Health. Furthermore, Keti is an active member of the Institute as she is part of the GOSH BRC Junior Faculty and Child Health Open Research Advisory Board.
Dr Daniel Wise completed his Bsc and MRes at the university of Exeter, where he specialized in plant-pathogen interactions and found a passion for Immunological research. Daniel spent a number of years as a researcher at the Institute of Metabolic sciences (IMS), Cambridge Institute of Medical Research (CIMR) and the Department of Pathology (University of Cambridge); where he investigated novel innate immune signaling, endoplasmic stress responses and antigen processing, presentation and recognition.
Daniel completed his PhD and postdoctoral studies at the University of Cambridge department of Pathology, specializing in MHC-mediated immunity. During this time, he established and conducted collaborative research projects with the Gurdon Institute, Cambridge veterinary school, Roslin Institute, Technical University of Munich, Ludwig Maximilian University of Munich and Institute of Molecular Genetics (Czech Academy of Sciences).
Following his PhD Daniel was awarded a Fellowship at the Technical University of Munich before moving into scientific Industry, where he worked in drug discovery and PROTAC drug
development before switching to R&D in the field of diagnostics. Currently Daniel is Laboratory Director at EDX medical and the Chief Scientific Officer at Origin Sciences, where he leads the development of new oncology diagnostic methods.
Have a question?
Our expert team is ready to help.